Our models / Other advanced therapies
Safety & evidence infrastructure shaped to each advanced therapy
Our models follow each therapy's delivery needs and safety profile. We provide the scalable infrastructure to make sure your health system or practice is ready to deliver the next wave of advanced therapies. For pharma and biotech companies, we help generate the evidence and demonstrate the pharmacovigilance an emerging therapy needs, from first trial through commercial delivery.
13+
advanced therapy assets supported
15+
global clinical trials, Phase I to IV
1,500+
advanced therapy episodes
60
peer-reviewed papers and abstracts
How we tailor the model
Built around each therapy's safety profile
Every advanced therapy has its own toxicities, its own timing, and its own signals. We start from the safety profile and build the clinical response around it, instead of fitting the therapy to a model built for something else.
01
Map the risk window
When do toxicities appear? After infusion, around each step-up dose, after discharge, or between dosing visits. Monitoring is concentrated where risk is highest.
02
Choose the signals
The physiologic signals, symptoms, and assessments that show a toxicity forming, from heart rate, respiratory rate, SpO₂, and temperature to weight, ePROs, and virtual ICE assessments.
03
Set the intensity
From guided check-ins on a set schedule to passive, around-the-clock monitoring, with devices matched to the signals that matter.
04
Define the response
Alarm thresholds balanced for sensitivity and specificity, so real deterioration is caught without flooding nurses and sites with noise. Our Clinical Coordination Center acts on them under each site's protocols.
Automated check-ins
Scheduled readings and symptom check-ins through the Current Health app, for a lower, well-defined window of risk
24/7 detection & clinical oversight
Around-the-clock signals from our FDA-cleared wearable, for toxicities that can escalate quickly or present without fever
Support can step up around each dose, when risk is highest, and step back down between doses as risk falls.
What tailoring looks like
Different therapies, different windows of risk
Three types of therapy, and how the signals and response change with each. Every program's configuration is set with the sponsor and the treating sites.
Type of therapy
Window of risk
Signals that matter
Response
TIL therapy
The weeks after infusion and high-dose IL-2, while cytopenias and infection risk persist
Temperature, heart rate, blood pressure, SpO₂, and signs of infection
Fever and infection escalation per site protocol
Monoclonal antibodies
The days of each infusion course, when infusion reactions and CRS are most likely
Temperature, heart rate, blood pressure, and symptoms such as rash
Escalation of infusion reactions or CRS per site protocol
Antibody-drug conjugates
Slower onset, over days to weeks
Resting SpO₂ trend, where a drop of 2–4% over 1–3 days can be an early sign of interstitial lung disease
Prompt evaluation for interstitial lung disease
Therapeutic areas
Therapeutic areas we support
Health systems and community practices deliver CAR-T, bispecifics, TIL therapy, and monoclonal antibodies with Current Health today. Pharma and biotech companies also work with us on therapies in development across these areas.
Hematologic oncology
CAR-T and TCR-T therapies, including autologous, allogeneic, and in vivo. CD3 bispecific and trispecific T-cell engagers.
Indications Multiple myeloma, B-cell lymphomas, and B-cell leukemias
Solid tumor oncology
TIL therapy, monoclonal antibodies, and antibody-drug conjugates with pulmonary toxicity.
Indications Melanoma, and breast, lung, and gastric cancers
Autoimmune and rheumatology
CD19 and BCMA cell therapies and T-cell engagers moving into autoimmune disease.
Indications Lupus and lupus nephritis, systemic sclerosis, myositis, rheumatoid arthritis, and Sjögren's
Neurology
Cell therapies and T-cell engagers, plus anti-CD20 infusions where the label leaves a coverage gap.
Indications Generalized myasthenia gravis, stiff person syndrome, and multiple sclerosis
Endocrinology
Monoclonal antibody infusions with a defined window of risk during the treatment course.
Indications Type 1 diabetes
Rare disease
AAV and ex vivo gene therapies.
Indications Sickle cell disease, hemophilia, spinal muscular atrophy, and metachromatic leukodystrophy
For pharma and biotech
One partner, a program built for each product
Each asset gets its own safety monitoring, evidence plan, and data flow, designed around its safety profile and its stage of development. What stays the same is the partner that builds and runs it.
Evidence generation plan
Endpoints designed into the protocol from the start, not retrofitted to the data afterward.
Safety and pharmacovigilance protocols
Signals, thresholds, and escalation rules set to the asset's toxicity profile and to trial or label requirements.
Data handling
Where each data stream goes and in what format. Deidentified data flows to your EDC, clinical documentation to the treating site's EHR, and safety reports to your safety database.
Monitoring window and intensity
Sized to the at-risk window, from step-up dosing to recovery after discharge to months of ongoing dosing.
The partner behind every program. The same FDA-cleared platform, 24/7 Clinical Coordination Center, and in-house kit logistics, with experience running programs from Phase I trials through commercial delivery.
For health systems and community practices
Support for every advanced therapy you offer
Whether you plan to deliver advanced therapies through a central program or embed delivery in specialty services, we can configure protocols and visibility for your approach. Use our ready-to-run models for CAR-T, bispecifics, TIL therapy, and monoclonal antibodies, so each new therapy builds on what your teams already run.
- Evidence-based protocols for each therapy, reviewed and approved by your clinical leads
- The same 24/7 Clinical Coordination Center behind every patient, escalating to your on-call team per your protocols
- Quality reporting across your whole program, by therapy and site
Our research
Evidence beyond CAR-T
Our clinical research team works with partner sites and sponsors to study how monitoring can be shaped to different therapies, with 60 peer-reviewed papers and abstracts since 2023.
Bispecifics
Outpatient step-up dosing for bispecific T-cell engagers1
100%
of CRS events detected by monitoring, every event Grade 1
Immunotherapy · Lung
Early pneumonitis detection in stage III NSCLC2
15 min
mean time to intervention
A prospective, multi-institutional pilot using wearable monitoring to detect pneumonitis early in patients receiving immunotherapy after chemoradiation.
T-cell engager · Leukemia
Outpatient T-cell engager infusion with digital monitoring3
A phase 4 study of outpatient administration with digital monitoring in MRD-positive B-cell acute lymphoblastic leukemia.
Developing or delivering an advanced therapy?
Tell us about the therapy and its safety profile, and we'll show you how we'd shape monitoring, clinical coordination, and evidence around it.